Pulse Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on June 10, 2021, reporting an event that occurred on May 20, 2021. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol "PLSE".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate governance event rather than financial performance results.
Material Changes
On May 20, 2021, the Board of Directors amended the Pulse Biosciences, Inc. 2017 Inducement Equity Incentive Plan (the "Inducement Plan"). The amendment reserved an additional 1,000,000 shares of the Company's common stock for issuance under the plan. This amendment was adopted without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard disclosure that the plan description is a summary qualified by the full text of the plan. The Inducement Plan is designed to grant equity-based awards to individuals not previously employed by the Company as an inducement material to their entry into employment or in connection with a merger or acquisition.
Key Facts for Investor Verification
- The Company increased the share reserve for its Inducement Plan by 1,000,000 shares.
- The amendment was executed without stockholder approval under Nasdaq rules.
- Awards under this specific plan are restricted to new hires or acquisitions, not existing employees.
- The full text of the amended plan is filed as Exhibit 10.1.